Aramark (ARMK) Q2 2026 Earnings Call Transcript

Why It Matters

The results validate Aramark’s growth strategy, showing resilient demand, high client retention, and profitable new contracts that should drive earnings momentum and support shareholder value.

Key Takeaways

• Organic revenue $4.8B, up 5% despite calendar shift.
• International segment 13% organic growth, 19th double‑digit quarter.
• New healthcare contracts: Penn Medicine, RWJBarnabas Health.
• Adjusted operating income $263M, underlying 11% growth.
• AI‑driven supply chain improves efficiency, supports GPO expansion.

Pulse Analysis

Aramark posted $4.8 billion of organic revenue for the quarter, a 5 % increase year‑over‑year. Management said a calendar‑shift effect shaved roughly $125 million, meaning underlying growth would have been close to 8 %. The company highlighted record client‑retention rates in both U.S. and International segments, a rare achievement at this point in the fiscal year. International revenue surged more than 13 %, marking the nineteenth consecutive quarter of double‑digit expansion and underscoring the strength of Aramark’s global footprint. These results demonstrate that the firm’s core food‑service and support businesses remain resilient despite macro‑economic headwinds.

The quarter’s headline wins came from the healthcare arena, where Aramark secured multi‑year contracts with Penn Medicine and RWJBarnabas Health, together covering over 9,000 beds. Those agreements not only boost top‑line volume but also carry cost‑plus pricing that should accelerate profitability as services ramp up. In parallel, the Group Purchasing Organization (GPO) recorded more than $20 billion of contracted spend, driven by deeper penetration in hospitality venues such as theme parks, hotels, and cruise lines. AI‑enabled analytics and mobile chatbots are now embedded in the supply‑chain platform, delivering faster sourcing decisions and measurable efficiency gains.

Financially, adjusted operating income reached $263 million, a modest 1 % rise, but after stripping the calendar impact the metric reflects roughly 11 % underlying growth. Capital expenditures ran at about 4.5 % of revenue this quarter, reflecting the mobilization of new contracts, with an expected return to a 3.5 % run‑rate by year‑end. Aramark’s balance sheet remains strong, with $1.4 billion of cash and leverage projected below three‑times net debt to EBITDA. The reaffirmed guidance of 7‑9 % organic revenue growth and 20‑25 % adjusted EPS expansion positions the company as a compelling play for investors seeking exposure to stable, inflation‑linked food‑service revenues and technology‑driven margin improvement.